<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> is critical for the clinical progression of haematopoietic <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and depends on angiogenic factors </plain></SENT>
<SENT sid="1" pm="."><plain>Angiogenin is a powerful factor produced by neoplastic cells and host microenvironment </plain></SENT>
<SENT sid="2" pm="."><plain>High levels of soluble angiogenin (sAng) correlate with a poor prognosis in patients affected by <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, but no data are available on sAng in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (CMD) </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, in this study we investigated the clinical significance of the angiogenin in sera of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>) (n = 14) or <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythaemia</z:e> (ET) (n = 20), and correlated them with those of soluble transforming growth factor-beta(1) (sTGF beta(1)) </plain></SENT>
<SENT sid="4" pm="."><plain>Enzyme-linked immunosorbent assay detected (P &lt; 0.05) higher levels of sAng in CMD compared with healthy subjects (1026.74 +/- 464.60 pg/mL and 196.00 +/- 39.90 pg/mL, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>The highest levels of sAng were detected in <z:mp ids='MP_0005481'>CML</z:mp> patients (1349.23 +/- 549.55 pg/mL) </plain></SENT>
<SENT sid="6" pm="."><plain>Interestingly, <z:mp ids='MP_0005481'>CML</z:mp> patients who achieved haematological remission after interferon therapy showed circulating levels of angiogenin significantly (P &lt; 0.05) decreased when compared with those at diagnosis </plain></SENT>
<SENT sid="7" pm="."><plain>In ET patients, levels of angiogenin (889.34 +/- 267.66 pg/mL) and sTGF beta(1) (76.69 +/-6.08 pg/mL) were higher (P &lt; 0.05) compared with healthy controls (57.93 +/- 19.39 pg/mL) </plain></SENT>
<SENT sid="8" pm="."><plain>No correlation was found between levels of sAng and levels of sTGF beta(1) or platelet count among ET patients </plain></SENT>
<SENT sid="9" pm="."><plain>Our results show for the first time that elevated blood levels of angiogenin feature <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e>, suggesting a role of angiogenin in the pathogenesis of these diseases </plain></SENT>
</text></document>